Mundipharma EDO is part of the Mundipharma global network of privately-owned independent associated companies, which operate in over 120 countries worldwide. At Mundipharma EDO we develop therapies for patients around the world with rare or relapsed/refractory (difficult to treat) cancer, and investigate smart approaches to new cancer treatments from concept through to clinical development and regulatory approval.
We are passionate medical and operational oncology specialists, partnering with a wide network of clinical experts and consultants. Our sole focus is progressing treatments through the research and clinical development phase. Responsibility for delivering new cancer treatments to patients will be passed onto other members of the Mundipharma global network at the point of marketing authorisation.
The team at Mundipharma EDO operate a lean, agile research and development model; this allows us to implement a fast and successful development process by empowering all members of our team to form conclusions and make quick decisions. We have ambitious timelines for our oncology clinical trials programme and are currently focused on patient recruitment for trials in several relapsed/refractory blood cancers and advanced solid tumours.
Find out about the evolution of cancer therapy, unmet patient needs and the smart approaches Mundipharma EDO is exploring to pursue advances in cancer treatment.
A brief introduction to the company and its mission.
Press return to search